Summary of safety profile
In clinical studies involving 1680 patients, olopatadine was administered one to four times daily in both eyes for up to four months as monotherapy or adjunctive therapy to loratadine 10 mg. Approximately 4.5% of patients can be expected to experience adverse reactions associated with the use of olopatadine; however, only 1.6% of patients discontinued from the clinical studies due to these adverse reactions. No serious ophthalmic or systemic adverse reactions related to olopatadine were reported in clinical studies. The most frequent treatment-related adverse reaction was eye pain, reported at an overall incidence of 0.7%.
Tabulated list of adverse reactions
The following adverse reactions have been reported during clinical studies and post-marketing data and are classified according to the following convention: very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥ 1/1,000 to <1/100), rare (≥ 1/10,000 to <1/1000), very rare (<1/10,000) or not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
System Organ Classification | Frequency | Adverse Reactions |
Infections and infestations | Uncommon | rhinitis |
Immune system disorders | Not known | hypersensitivity, swelling face |
Nervous system disorders | Common | headache, dysgeusia |
| Uncommon | dizziness, hypoaesthesia |
| Not known | somnolence |
Eye disorders | Common | eye pain, eye irritation, dry eye, abnormal sensation in eyes |
| Uncommon | corneal erosion, corneal epithelium defect, corneal epithelium disorder, punctate keratitis, keratitis, corneal staining, eye discharge, photophobia, vision blurred, visual acuity reduced, blepharospasm, ocular discomfort, eye pruritus, conjunctival follicles, conjunctival disorder, foreign body sensation in eyes, lacrimatioincreased, erythema of eyelid, eyelid oedema, eyelid disorder, ocular hyperaemia |
| Not known | corneal oedema, eye oedema, eye swelling, conjunctivitis, mydriasis, visual disturbance, eyelid margin crusting |
Respiratory, thoracic, and mediastinal disorders | Common | nasal dryness |
Not known | dyspnoea, sinusitis |
Gastrointestinal disorders | Not known | nausea, vomiting, |
Skin and subcutaneous tissue disorders | Uncommon | dermatitis contact, skin burning sensation, dry skin |
Not known | dermatitis, erythema |
General disorders and administration site conditions | Common | fatigue |
Not known | asthenia, malaise |
Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged corneas.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at:www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.